SYMPTOMATIC DERMOGRAPHISM
Clinical trials for SYMPTOMATIC DERMOGRAPHISM explained in plain language.
Never miss a new study
Get alerted when new SYMPTOMATIC DERMOGRAPHISM trials appear
Sign up with your email to follow new studies for SYMPTOMATIC DERMOGRAPHISM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for chronic hives sufferers: drug targets root cause
Disease control OngoingThis study tests a new medication, remibrutinib, for people with chronic hives caused by triggers like cold, heat, or scratching (chronic inducible urticaria). The drug aims to control symptoms better than standard antihistamines. About 362 adults will take the drug or a placebo …
Matched conditions: SYMPTOMATIC DERMOGRAPHISM
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug shows promise for Long-Term control of chronic hives
Disease control OngoingThis study is testing the long-term safety and effectiveness of a drug called briquilimab for people with chronic hives. It includes 67 participants who have already completed a previous trial with the same drug. The goal is to see if briquilimab remains safe and helps control hi…
Matched conditions: SYMPTOMATIC DERMOGRAPHISM
Phase: PHASE2 • Sponsor: Jasper Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC